<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03385239</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 678354-CS2</org_study_id>
    <nct_id>NCT03385239</nct_id>
  </id_info>
  <brief_title>Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 678354 Administered Subcutaneously to Patients With Hypertriglyceridemia and Established Cardiovascular Disease (CVD) or at a High Risk for CVD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akcea Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Akcea Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to&#xD;
      evaluate the safety, including tolerability, of ISIS 678354 and to assess the efficacy of&#xD;
      different doses and dosing regimens of ISIS 678354 for reduction of serum triglyceride (TG)&#xD;
      levels in participants with hypertriglyceridemia and established CVD or at a high risk for&#xD;
      CVD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 5, 2018</start_date>
  <completion_date type="Actual">February 25, 2020</completion_date>
  <primary_completion_date type="Actual">November 25, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of different doses and dosing regimens of ISIS 678354 on the reduction in serum triglyceride (TG) levels from baseline at the primary analysis time point.</measure>
    <time_frame>6 months</time_frame>
    <description>The comparison of percent change from baseline to primary analysis time point in fasting serum TG levels between ISIS 678354 treated groups and pooled placebo group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The safety of ISIS 678354 by the incidence of treatment-emergent adverse events.</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>The safety of ISIS 678354 will be assessed by determining adverse effects by dose. Safety results in subjects dosed with ISIS 678354 will be compared with those from subjects dosed with placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of different doses and dosing regimens of ISIS 678354 on serum triglyceride (TG) levels from baseline at the primary analysis time point.</measure>
    <time_frame>6 months</time_frame>
    <description>The comparison of the proportion of patients who achieve serum TG ≤ 150 mg/dL, and the proportion of patients achieving TG ≤ 100 mg/dL as compared to placebo at the primary analysis time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of ISIS 678354 on serum levels of apolipoprotein C-III (apoC-III).</measure>
    <time_frame>6 months</time_frame>
    <description>Percent change from baseline at the primary analysis time point in apoCIII will be compared between each ISIS 678354 treatment groups and pooled placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of ISIS 678354 on serum levels of cholesterol parameters.</measure>
    <time_frame>6 months</time_frame>
    <description>Percent change from baseline at the primary analysis time point in cholesterol parameters will be compared between each ISIS 678354 treatment groups and pooled placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of ISIS 678354 on serum levels of apolipoprotein B100 (apoB).</measure>
    <time_frame>6 months</time_frame>
    <description>Percent change from baseline at the primary analysis time point in apoB will be compared between each ISIS 678354 treatment groups and pooled placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of ISIS 678354 on serum levels of apolipoprotein A-1 (apoA-I).</measure>
    <time_frame>6 months</time_frame>
    <description>Percent change from baseline at the primary analysis time point in apoA-I will be compared between each ISIS 678354 treatment groups and pooled placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Cmax of ISIS 678354 across different doses and dose regimens.</measure>
    <time_frame>6 months</time_frame>
    <description>Cmax of ISIS 678354 in plasma will be calculated for the treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Tmax of ISIS 678354 across different doses and dose regimens.</measure>
    <time_frame>6 months</time_frame>
    <description>Tmax of ISIS 678354 in plasma will be calculated for the treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma AUC values of ISIS 678354 across different doses and dose regimens.</measure>
    <time_frame>6 months</time_frame>
    <description>Plasma AUC values of ISIS 678354 will be calculated for the treatment groups.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Pooled Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in each cohort (A,B,C and D) were randomized to receive placebo at a dose-matched volume of study drug (ISIS 678354).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A: ISIS 678354: 10 mg Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A participants received 10 milligrams (mg) ISIS 678354, subcutaneous (SC) injection, once every 4 weeks (Q4W), for up to 49 weeks and a maximum of 13 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C: ISIS 678354: 15 mg Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort C participants received 15 mg ISIS 678354, SC injection, once every 2 weeks (Q2W) for up to 51 weeks and a maximum of 26 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D: ISIS 678354: 10 mg QW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort D participants received 10 mg ISIS 678354, SC injection, once weekly (QW) for up to 52 weeks and a maximum of 52 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: ISIS 678354: 50 mg Q4W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort B participants received 50 mg ISIS 678354, SC injection, once Q4W for up to 49 weeks and a maximum of 13 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 678354</intervention_name>
    <description>ISIS 678354 solution for SC injection.</description>
    <arm_group_label>Cohort A: ISIS 678354: 10 mg Q4W</arm_group_label>
    <arm_group_label>Cohort B: ISIS 678354: 50 mg Q4W</arm_group_label>
    <arm_group_label>Cohort C: ISIS 678354: 15 mg Q2W</arm_group_label>
    <arm_group_label>Cohort D: ISIS 678354: 10 mg QW</arm_group_label>
    <other_name>AKCEA-APOCIII-LRx, IONIS-APOCIII-LRx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sterile Normal Saline (0.9% NaCl).</description>
    <arm_group_label>Pooled Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of CVD (defined as documented coronary artery disease, stroke, or&#xD;
             peripheral artery disease).&#xD;
&#xD;
          -  Fasting serum triglycerides (TG) greater than or equal to (≥) 200 milligrams per&#xD;
             deciliter (mg/dL) (≥ 2.3 millimoles per liter (mmol/L)) and less than or equal to (≤)&#xD;
             500 mg/dL (≥ 5.7 mmol/L) at Screening.&#xD;
&#xD;
          -  Fasting TG ≥ 200 mg/dL and ≤ 500 mg/dL at Qualification visit.&#xD;
&#xD;
          -  Must be on standard-of-care preventative therapy for known CVD risk factors.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Within 6 months of Screening: acute coronary syndrome, major cardiac surgery, or&#xD;
             stroke/transient ischemic attack (TIA).&#xD;
&#xD;
          -  Within 3 months of Screening: coronary, carotid, or peripheral arterial&#xD;
             revascularization, major non-cardiac surgery, or lipoprotein apheresis.&#xD;
&#xD;
          -  Heart failure New York Heart Association (NYHA) class IV.&#xD;
&#xD;
          -  Type 1 diabetes mellitus.&#xD;
&#xD;
          -  Type 2 diabetes mellitus with any of the following:&#xD;
&#xD;
               -  Newly diagnosed within 12 weeks of Screening.&#xD;
&#xD;
               -  Glycated hemoglobin (HbA1c) ≥ 9.0% at Screening.&#xD;
&#xD;
               -  Recent change in anti-diabetic pharmacotherapy (change in dosage or addition of&#xD;
                  new medication within 12 weeks of Screening [with the exception of ± 10 units of&#xD;
                  insulin].&#xD;
&#xD;
          -  Body Mass Index (BMI) greater than (&gt;) 40 kilograms per square meter (kg/m^2).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Cottonwood</city>
        <state>Arizona</state>
        <zip>86326</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <zip>95608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037-7410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <zip>91763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33434</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Munster</city>
        <state>Indiana</state>
        <zip>46321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Cooperstown</city>
        <state>New York</state>
        <zip>13326</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Lansdale</city>
        <state>Pennsylvania</state>
        <zip>19446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 6V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Brossard</city>
        <state>Quebec</state>
        <zip>J4Z 2K9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8Y 6S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V 4W2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 1, 2017</study_first_submitted>
  <study_first_submitted_qc>December 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2017</study_first_posted>
  <disposition_first_submitted>November 19, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>November 19, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 20, 2020</disposition_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AKCEA-APOCIII-LRx</keyword>
  <keyword>IONIS-APOCIII-LRx</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>Metabolic Disease</keyword>
  <keyword>Hyperlipidemia</keyword>
  <keyword>Cardiac Disease</keyword>
  <keyword>Lipid Metabolism Disorders</keyword>
  <keyword>Triglycerides High</keyword>
  <keyword>Vascular Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

